Triplet regimens incorporating an anti-angiogenic agent have been explored to further enhance PARP-PD-1/PD-L1 efficacy, based on the ability of vascular endothelial growth factor (VEGF) blockade to normalize vasculature, improve immune-cell trafficking, and modulate the tumor microenvironment [31,32]. The gene discussed is CD274; the disease is neoplasm.